<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195766</url>
  </required_header>
  <id_info>
    <org_study_id>O-ESHAP-LH-2009</org_study_id>
    <secondary_id>2009-016026-13</secondary_id>
    <nct_id>NCT01195766</nct_id>
  </id_info>
  <brief_title>Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma</brief_title>
  <official_title>Phase II-study Using Ofatumumab and ESHAP Followed by Autologous Trasplant of Hemopoietic Precursors for the Treatment of Classic Hodgkin's Lymphoma on Relapse, Partial Response or Refractory to First Line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to analyze the efficacy of O-ESHAP treatment for Hodgkin's lymphome
      patients that have a first line chemotherapy treatment failure due to refractoriness, partial
      response or relapsed.

      In the same way, mortality, global survival and free-progression survival after O-ESHAP
      treatment and TAPH will also analyzed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to the above:

        -  To asses the complete response rate after O-ESHAP.

        -  To asses the toxicity of O-ESHAP regimen

        -  To asses the stem cells mobilization capacity of O-ESHAP regimen

        -  To evaluate the final results of the whole procedure (O-ESHAP followed by high-dose
           chemotherapy and ASCT): transplant-related mortality (TRM), overall survival (OS), and
           progression free survival (PFS)

        -  To investigate the correlation between the overall response and CD20 expression by
           tumoral cells.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of the global response rate (complete responses + partial responses) after O-ESHAP treatment</measure>
    <time_frame>4 years follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To analyze the complete response rate after O-ESHAP treatment. Further secondary outcomes as described in study summary</measure>
    <time_frame>4 years follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>Ofatumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ofatumumab in addition to ESHAP therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab</intervention_name>
    <description>Ofatumumab in addition with ESHAP therapy</description>
    <arm_group_label>Ofatumumab</arm_group_label>
    <other_name>ARZERRA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed relapsed, partial response or refractory
             classical HL after first line chemotherapy. They will be included irrespective of CD20
             expression on HRS cells. CD20 expression will be analyzed on all available biopsies
             and this data will be recorded for further evaluation.

          -  Age 18 to 65 years. Patient &gt;65 and &lt;70 years old with ECOG &lt; 2 and absence of
             comorbidities will be included in the study if considered adequate by the
             investigator.

          -  Leucocytes &gt; 3,0 x 109/L and platelets &gt; 100 x 109/L.

          -  ECOG &lt; 2.

          -  No major organ dysfunction.

          -  Written informed consent.

          -  HIV negative.

          -  No active hepatitis B or C infection.

          -  Availability of histological report of biopsy at diagnosis or at relapse and
             availability of biopsy to be revised by reference pathologists.

          -  Absence of other neoplasia, except basocellular tumor or carcinoma of the uterine
             cervix in situ.

          -  Contraception measures in fertile females.

        Exclusion Criteria:

          -  Subjects who have current active hepatic or biliary disease

          -  presence of pathology that would contraindicate the administration of chemotherapy

          -  HIV positive

          -  Hepatitis B or C infection

          -  history of other malignancies in addition to those specified in the inclusion criteria

          -  informed consent not signed

          -  Pregnant and / or breast-feeding or reproductive capacity adults who do not use an
             effective method of birth control during study treatment and at least six months
             later. An effective method is that used at least one barrier mechanism.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Martínez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Clinic i Provincial de Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Catalan de Oncologia</name>
      <address>
        <city>L'Hospitalet</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2010</study_first_posted>
  <last_update_submitted>February 23, 2016</last_update_submitted>
  <last_update_submitted_qc>February 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin</keyword>
  <keyword>Ofatumumab</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

